1 Recommendations
KEYWORDS: miraq, graft, cost, flow, cabg, surgery, patients, veriq, costs, grafts, clinical, assessment, pulsatility index, index, pulsatility

in-between study heterogeneity. There was, therefore, not enough high-quality evidence to justify any changes to the guidance. 5.14 The EAC revised the model to reflect 2021 costs and changes to the cost of the technology. This reduced the cost saving compared with clinical assessment from £141 to £80.27. The EAC found that there was no justification for updating the clinical parameters of the economic model. Further details of the revised model are in the cost update in the review decision from June 2022. [2022] 6 Conclusions 6.1 The committee concluded that the available clinical and cost evidence supported the case for adopting the MiraQ system in the NHS for routine intraoperative graft flow assessment in patients having coronary artery bypass graft surgery.
